XmAb942
PreclinicalBiologic
XmAb942 is one of 8 biologic programs targeting Ulcerative Colitis (UC). It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Ulcerative Colitis (UC)
#DrugCompanyPhaseTrials
1Rinvoq
AbbVieApproved
Omvoh
Eli LillyApproved
Vancocin
HHikma Pharmaceuticals LLC
Phase 2
Ponvory
VVanda Pharmaceuticals
Phase 3
AC-101
AAccro Bioscience (Suzhou) Limited
Phase 2
Alinia
RRomark Laboratories L.C.
Preclinical
Alpha-0261
AAlphaMol Science Ltd. (Shanghai)
Phase 1
XmAb942
XXencor, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Ulcerative Colitis (UC)1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for XmAb942. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Preclinical[1]
- Company
- XXencor, Inc.